KRAS G12C Mutations in NSCLC: From Target to Resistance.

KRAS G12C NSCLC adagrasib resistance sotorasib

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
21 May 2021
Historique:
received: 15 03 2021
revised: 17 05 2021
accepted: 20 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 3 6 2021
Statut: epublish

Résumé

Lung cancer represents the most common form of cancer, accounting for 1.8 million deaths globally in 2020. Over the last decade the treatment for advanced and metastatic non-small cell lung cancer have dramatically improved largely thanks to the emergence of two therapeutic breakthroughs: the discovery of immune checkpoint inhibitors and targeting of oncogenic driver alterations. While these therapies hold great promise, they face the same limitation as other inhibitors: the emergence of resistant mechanisms. One such alteration in non-small cell lung cancer is the Kirsten Rat Sarcoma (

Identifiants

pubmed: 34064232
pii: cancers13112541
doi: 10.3390/cancers13112541
pmc: PMC8196854
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

BMC Cancer. 2010 Mar 22;10:105
pubmed: 20307299
Cell. 2014 Jul 3;158(1):171-84
pubmed: 24954536
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):
pubmed: 29229670
Cancer Res. 2012 May 15;72(10):2457-67
pubmed: 22589270
Cancer Discov. 2012 Mar;2(3):227-35
pubmed: 22448344
Cancer Discov. 2021 Apr 6;:
pubmed: 33824136
Acta Crystallogr D Struct Biol. 2017 Dec 1;73(Pt 12):970-984
pubmed: 29199977
Clin Cancer Res. 2020 Apr 1;26(7):1538-1540
pubmed: 32001483
Cancer Cell. 2009 Jun 2;15(6):489-500
pubmed: 19477428
Expert Rev Anticancer Ther. 2014 Aug;14(8):869-71
pubmed: 24928447
J Thorac Oncol. 2021 May 7;:
pubmed: 33971321
Sci Signal. 2011 Mar 29;4(166):pe16
pubmed: 21447797
Clin Transl Gastroenterol. 2016 Mar 24;7:e157
pubmed: 27010960
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Ann Oncol. 2014 Dec;25(12):2378-2385
pubmed: 25294886
Front Oncol. 2019 Apr 16;9:264
pubmed: 31058078
J Cancer Res Clin Oncol. 2020 Jan;146(1):43-52
pubmed: 31705294
ACS Med Chem Lett. 2016 Nov 30;8(1):61-66
pubmed: 28105276
N Engl J Med. 2020 Sep 24;383(13):1207-1217
pubmed: 32955176
Clin Cancer Res. 2019 Jan 15;25(2):796-807
pubmed: 30327306
Lancet Oncol. 2012 Aug;13(8):773-81
pubmed: 22805291
Nature. 2019 Nov;575(7782):299-309
pubmed: 31723286
Nature. 2020 Jan;577(7790):421-425
pubmed: 31915379
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2545-2550
pubmed: 30683716
Mol Cell. 2019 Dec 19;76(6):872-884.e5
pubmed: 31606273
Clin Cancer Res. 2016 Jun 1;22(11):2778-2790
pubmed: 27001312
Cancer Discov. 2018 Oct;8(10):1210-1212
pubmed: 30279193
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2551-2560
pubmed: 30683722
Science. 2016 Feb 5;351(6273):604-8
pubmed: 26841430
JAMA. 2017 May 9;317(18):1844-1853
pubmed: 28492898
J Biol Chem. 2011 Feb 4;286(5):3323-31
pubmed: 21098031
N Engl J Med. 2019 Oct 24;381(17):1632-1643
pubmed: 31566309
Nature. 2019 Nov;575(7781):217-223
pubmed: 31666701
Genes Cancer. 2011 Mar;2(3):261-74
pubmed: 21779497
Sci Signal. 2011 Mar 29;4(166):ra17
pubmed: 21447798
Cell. 2017 Aug 10;170(4):605-635
pubmed: 28802037
Cancer Treat Rev. 2020 Apr;85:101978
pubmed: 32062493
Semin Cell Dev Biol. 2016 Oct;58:127-35
pubmed: 27297136
Cell Chem Biol. 2017 Aug 17;24(8):1005-1016.e3
pubmed: 28781124
Cancer Discov. 2020 Jan;10(1):54-71
pubmed: 31658955
Nat Rev Cancer. 2018 Dec;18(12):767-777
pubmed: 30420765
Cell. 2017 Feb 23;168(5):817-829.e15
pubmed: 28215705
Oncogene. 2018 May;37(18):2444-2455
pubmed: 29453361
Ann Oncol. 2015 May;26(5):894-901
pubmed: 25722381
EMBO Rep. 2005 May;6(5):432-7
pubmed: 15864294
Nat Rev Clin Oncol. 2018 May;15(5):273-291
pubmed: 29508857
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Nat Commun. 2018 Sep 7;9(1):3646
pubmed: 30194290
J Cancer Res Clin Oncol. 2019 Jan;145(1):241-251
pubmed: 30368666
Cell Signal. 2008 Mar;20(3):453-9
pubmed: 17993263
J Natl Cancer Inst. 2012 Feb 8;104(3):228-39
pubmed: 22247021
Cancer Discov. 2016 Mar;6(3):316-29
pubmed: 26739882
J Thorac Oncol. 2014 Oct;9(10):1513-22
pubmed: 25170638
J Clin Invest. 2015 Jan;125(1):222-33
pubmed: 25437878
Nat Commun. 2017 Oct 23;8(1):1090
pubmed: 29061961
Clin Cancer Res. 2020 Apr 1;26(7):1633-1643
pubmed: 31776128
Nat Med. 2018 Jul;24(7):961-967
pubmed: 29808006
Cancer Discov. 2012 Mar;2(3):214-26
pubmed: 22585993
Cell. 2018 Feb 8;172(4):857-868.e15
pubmed: 29336889
Sci Transl Med. 2019 Sep 18;11(510):
pubmed: 31534020
Nature. 2013 Nov 28;503(7477):548-51
pubmed: 24256730
Clin Cancer Res. 2012 Nov 15;18(22):6169-77
pubmed: 23014527
Nat Cell Biol. 2002 Aug;4(8):621-5
pubmed: 12134164
FASEB J. 1995 Jun;9(9):726-35
pubmed: 7601337
Mol Cancer. 2018 Feb 19;17(1):33
pubmed: 29455666
Clin Cancer Res. 2012 Dec 15;18(24):6580-7
pubmed: 23087408
Cancer Discov. 2019 Jun;9(6):738-755
pubmed: 30952657
Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4574-9
pubmed: 23487764
Nature. 1998 Jul 23;394(6691):337-43
pubmed: 9690470
J Biol Chem. 2019 Jun 21;294(25):9937-9948
pubmed: 31088913
Oncogene. 2008 Oct 27;27(50):6473-88
pubmed: 18955974
J Biol Chem. 2017 Aug 4;292(31):12981-12993
pubmed: 28630043
Cell. 2012 Apr 13;149(2):307-21
pubmed: 22500798
Cell Death Differ. 2020 May;27(5):1451-1454
pubmed: 32205856
Mol Cancer Ther. 2021 Jun;20(6):975-985
pubmed: 33722854
Nat Med. 2018 Jul;24(7):968-977
pubmed: 29808010

Auteurs

Alfredo Addeo (A)

Swiss Cancer Center Leman, Oncology Department, Switzerland University of Geneva, University Hospital Geneva, 1205 Geneva, Switzerland.

Giuseppe Luigi Banna (GL)

Oncology Department, Portsmouth Hospitals NHS Trust, Portsmouth PO2 8QD, UK.

Alex Friedlaender (A)

Swiss Cancer Center Leman, Oncology Department, Switzerland University of Geneva, University Hospital Geneva, 1205 Geneva, Switzerland.
Oncology Service, Clinique Générale Beaulieu, 1206 Geneva, Switzerland.

Classifications MeSH